Back to Care packages

    Fat-Loss Peptide Care · Founding plan

    Lean-mass-first. Coached, not just prescribed.

    Coaching for nutrition, strength, sleep and recovery around clinician-led weight management. We distinguish approved metabolic medicines from investigational peptides; an early trial result is not a prescription product. GLP-1 users have a dedicated Care plan.

    Stacked horizontal bands in soft purple on cream paper, each thinner than the previous — an abstract tapering rhythm holding a solid baseline below, representing lean-mass protection while total load reduces

    Evidence reviewed · 2026-11-16

    What the evidence actually supports

    Semaglutide & Tirzepatide

    These medicines have substantial human evidence for defined metabolic indications. Approval belongs to a product, indication and country—not to every vial bearing the molecule's name. Appetite effects are not proof of nervous-system regulation or dorsal-vagal shutdown.

    Protect nutrition, strength and hydration with an individual plan. An Anchor, supplement bundle or fixed fasting window is not a medical prerequisite. Obesity treatment may be long term; stopping commonly leads to regain, and a taper is not proven to prevent it. Do not change prescribed treatment based on wearable readiness alone.

    Pills, new pens and the metabolic pipeline

    Oral Wegovy (semaglutide 25 mg) was approved in the US in December 2025 and in the EU on 15 July 2026; in OASIS 4 (307 adults without diabetes) mean weight change at 64 weeks was −13.6% versus −2.2% with placebo. On 1 April 2026 FDA approved Foundayo (orforglipron), the first once-daily GLP-1 pill without food or water timing rules; worth knowing that orforglipron is a small molecule, not a peptide at all. Wegovy injection also holds a US accelerated MASH indication (August 2025) for noncirrhotic disease with F2–F3 fibrosis; that is not a liver-detox or longevity claim.

    A pill changes the route, not the biology: appetite still drops, so protein, strength training and hydration still decide what the lost weight is made of. Approval belongs to a product, indication and country; EU authorisation of oral Wegovy does not confirm Portuguese supply or reimbursement, and Foundayo's approval verified here is US-only.

    Semaglutide: the eye-safety update

    On 6 June 2025, EMA concluded that NAION, an optic-nerve condition, is a very rare adverse effect of semaglutide. Observational estimates in adults with type 2 diabetes corresponded to about one additional case per 10,000 person-years; that estimate is not a risk calculation for every individual.

    Sudden vision loss or rapidly worsening eyesight requires urgent medical assessment. This warning is specific to semaglutide, not established as an identical risk for all peptides or incretin medicines. The clinician handles treatment decisions.

    Retatrutide: the most-searched peptide nobody can legally sell

    Retatrutide, Lilly's weekly GIP, GLP-1 and glucagon triple agonist, topped 2026 peptide searches before any regulator had approved it. In the phase 3 TRIUMPH-1 trial (2,339 adults without diabetes), company topline results reported mean weight loss of 28.3% on 12 mg at 80 weeks versus 2.2% on placebo. TRIUMPH-4 (knee osteoarthritis) reported 28.7% at 68 weeks; TRIUMPH-2 (type 2 diabetes, published in The Lancet) reported 20.8% at 80 weeks. Lilly plans to file with FDA in the first quarter of 2027.

    Retatrutide is not authorised in the US, UK or EU, so anything sold as 'reta' outside a trial is an unlicensed product of unknown content. In October 2026 the MHRA seized more than 12,000 fake retatrutide and tirzepatide pens in Birmingham. Trial results came with screening, supervised dose escalation and follow-up; a grey-market vial supplies none of those.

    Amylin: the second appetite signal

    Amylin is a satiety hormone released with insulin, and it is the next lane after GLP-1. CagriSema (cagrilintide plus semaglutide) reported −20.4% versus −3.0% at 68 weeks in REDEFINE 1 and was still awaiting a US decision at this review. Lilly's selective amylin agonist eloralintide produced 9.5–20.1% mean weight loss versus 0.4% with placebo at 48 weeks in a 263-person phase 2 trial (Billings et al., The Lancet, 2025), and has moved into phase 3.

    No approval of CagriSema or eloralintide was verified on 16 November 2026. Vials sold online as cagrilintide or 'amylin' are not these trial products. A second appetite brake makes under-eating easier, which makes protein and strength work more important, not less.

    Tesamorelin

    Tesamorelin (Egrifta) has been FDA-approved since 2010 for one use: reducing excess abdominal fat in adults with HIV-associated lipodystrophy. Its popularity as a general 'visceral fat' peptide borrows that label. The current label states it is not indicated for weight-loss management and that long-term cardiovascular safety has not been established.

    It raises IGF-1, can worsen glucose tolerance and is contraindicated with active malignancy or pituitary disruption. Outside its indication, the decision belongs to a prescriber who is monitoring those numbers.

    MOTS-c

    MOTS-c is a peptide encoded in mitochondrial DNA. Changhan Lee and colleagues in Pinchas Cohen's lab (Cell Metabolism, 2015) showed it acting on AMPK energy signalling and diet-induced obesity in mice. That is a strong mechanism with a thin human chapter: FDA's July 2026 briefing found human safety and effectiveness data insufficient, even though MOTS-c is in the October 2026 US compounding policy.

    No validated human weight-loss or longevity regimen exists. Exercise is the best-studied way to recruit the same energy-sensing machinery, and it comes with a safety record.

    The plan = Clinician intake + Monthly. Both required. Labs billed separately.

    Step 1 · required

    Clinician intake + protocol review

    60 min with the plan's clinician. Reviews your prescribing clinician's peptide protocol, baseline labs and any cycle history — then writes the coaching plan into your Protocols app. Kokorology does not prescribe. Any labs are billed separately by the lab and are not included in the €150.

    Step 2 · required

    Fat-Loss Peptide Care plan

    Founding price. Locked while you stay subscribed.

    Cancel monthly anytime. Add-on doctor consults €150+VAT, add-on Sabin 1:1s €110+VAT — only when needed.

    Prefer to talk first? Book a paid Discovery Call with Sabin — €110 →

    Sabin — founder of Kokorology and lead coach on the Care plan

    Your coach

    Sabin — founder of Kokorology

    Built the methodology after rebuilding her own nervous system out of burnout. Now coaches the people the protocol alone can't reach — founders, clinicians and high-load humans who need this landing on a body that can actually carry it.

    • ●10+ years coaching founders, clinicians and high-load humans through nervous system rebuilds
    • ●Author of the Kokorology Nervous System Management methodology & the 7 Anchor protocols
    • ●Certified coach in nutrition, yoga, sleep, rest & restore, somatics, reformer and barre — works alongside your clinician
    • ●Coaches founders, clinical leadership teams and athletes 1:1
    • ●Featured across press, podcasts and corporate wellness programmes

    What's included every month

    Why the plan exists

    Where fat-loss peptides fail without coaching

    These are coaching scenarios, not trial outcomes or promises that a peptide works. We track the everyday pillars, review uncertainty and route clinical decisions to your clinician.

    Cycle start
    Peptide aloneDeficit + peptide

    Weight drops fast. Protein under-target. Resistance training missing. Lean mass leaving.

    + Fat-Loss Peptide CareLean-mass floor set

    Protein floor by bodyweight and resistance cadence set day one. Nutrition and strength monitored without promising selective fat loss.

    Week 2–4
    Peptide aloneSleep and HRV drop

    Restrict harder to keep the scale moving. Sleep short, HRV drops, refuel skipped.

    + Fat-Loss Peptide CareAutonomic floor held

    Protocols app flags the drop. Sabin adjusts deficit ceiling and refuel to hold HRV.

    Month 2–3
    Peptide aloneMetabolic adaptation

    Progress stalls. Add more peptide, more restriction. Muscle keeps leaving.

    + Fat-Loss Peptide CareRefeed and resistance

    Refeed windows and resistance cadence layered in. Changes reviewed without guaranteeing metabolic or weight outcomes.

    Cycle end
    Peptide aloneRapid regain

    Peptide stops. Fat regains fast, muscle doesn't. Composition worse than start.

    + Fat-Loss Peptide CareOff-ramp planned

    Off-ramp built with your clinician's protocol. Nutrition and strength monitored; outcomes vary.

    Month 6–12
    Peptide aloneYo-yo

    Restart, restart, restart. Cycles stack without strategy.

    + Fat-Loss Peptide CareQuarterly review

    Sabin reviews composition and labs quarterly. Medication decisions stay with your clinician.

    Peptide prescribing decisions stay with your own clinician. Kokorology is not a prescribing service. GLP-1 users route to /glp1-care.

    The math, out loud

    Bought à la carte, these pieces add up to more than the plan. The Anchor protocol, full Daily Hacks library, and the Movement library (22 traditions) are folded in. Labs are ordered by your GP; Sabin reads them with you.

    Sabin monthly 1:1€110
    Weekly digital check-ins (×4)€100
    Protocols app (lean-mass protocol preloaded)€25
    Composition + peptide-cycle coachingincluded
    Anchor protocol (one-off)€40included
    Daily Hacks library€19included
    Movement library (22 traditions)€19included
    Total if bought separately€313
    Founding plansave €68/mo€245/mo

    What actually happens in each consult

    Sabin 1:1 — 45 min (€110 + VAT)

    Reads your clinician's peptide protocol alongside your composition, protein intake, resistance cadence and sleep. Writes the month's lean-mass-first plan into your Protocols app.

    Weekly digital check-in

    You send the week's pattern (Protocols app + cycle log). Sabin sends back one adjustment — not ten.

    How recommendations are handled

    Every recommendation lands in your Protocols app as a dated note you can show your clinician. Red flags (unexpected reactions, rapid lean-mass loss, mood collapse) route to your clinician — coaching stays coaching.

    Common questions

    Is this for GLP-1 (semaglutide, tirzepatide)?

    No — GLP-1 users have a dedicated plan at /glp1-care with a prescribing-doctor intake. Fat-Loss Peptide Care covers non-GLP-1 fat-loss peptide protocols.

    Do you prescribe the peptide?

    No. Kokorology is not a prescribing service. You bring the prescription from your own clinician; Sabin coaches the body around it.

    What does the Protocols app do?

    It's preloaded with the lean-mass protocol — nutrition, resistance cadence, sleep floor, refuel window, cycle log.

    Can I cancel?

    Yes — monthly plan, cancel anytime. Your founding price stays locked as long as the subscription runs.